25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Aldeyra The
Buy, Hold or Sell?

Let's analyze Aldeyra together

I guess you are interested in Aldeyra The. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aldeyra The. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aldeyra The

I send you an email if I find something interesting about Aldeyra The.

1. Quick Overview

1.1. Quick analysis of Aldeyra (30 sec.)










1.2. What can you expect buying and holding a share of Aldeyra? (30 sec.)

How much money do you get?

How much money do you get?
$0.02
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$1.43
Expected worth in 1 year
$0.79
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$-0.62
Return On Investment
-12.8%

For what price can you sell your share?

Current Price per Share
$4.82
Expected price per share
$3.14 - $6.1695
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aldeyra (5 min.)




Live pricePrice per Share (EOD)
$4.82
Intrinsic Value Per Share
$-7.05 - $-4.18
Total Value Per Share
$-5.62 - $-2.75

2.2. Growth of Aldeyra (5 min.)




Is Aldeyra growing?

Current yearPrevious yearGrowGrow %
How rich?$85m$135.2m-$31.1m-29.9%

How much money is Aldeyra making?

Current yearPrevious yearGrowGrow %
Making money-$11.1m-$11m-$148.7k-1.3%
Net Profit Margin-302.6%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Aldeyra (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#382 / 950

Most Revenue
#675 / 950

Most Profit
#587 / 950

Most Efficient
#569 / 950
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aldeyra?

Welcome investor! Aldeyra's management wants to use your money to grow the business. In return you get a share of Aldeyra.

First you should know what it really means to hold a share of Aldeyra. And how you can make/lose money.

Speculation

The Price per Share of Aldeyra is $4.82. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aldeyra.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aldeyra, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.43. Based on the TTM, the Book Value Change Per Share is $-0.16 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aldeyra.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.25-5.3%-0.19-3.9%-0.19-4.0%-0.21-4.3%-0.16-3.4%
Usd Book Value Change Per Share-0.22-4.6%-0.16-3.3%-0.16-3.4%0.030.6%0.030.7%
Usd Dividend Per Share0.000.0%0.000.1%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.22-4.6%-0.15-3.2%-0.16-3.4%0.030.6%0.030.7%
Usd Price Per Share5.39-3.87-7.99-6.20-6.66-
Price to Earnings Ratio-5.31--6.31--10.89--8.03--14.86-
Price-to-Total Gains Ratio-24.29--41.04--51.44--30.52--26.87-
Price to Book Ratio3.77-2.31-3.53-3.43-10.01-
Price-to-Total Gains Ratio-24.29--41.04--51.44--30.52--26.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.82
Number of shares207
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.160.03
Usd Total Gains Per Share-0.150.03
Gains per Quarter (207 shares)-32.046.13
Gains per Year (207 shares)-128.1624.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
14-132-13812415
27-264-26614840
311-395-39427165
414-527-52239590
518-659-6504119115
622-791-7784143140
725-923-9065167165
829-1054-10346190190
933-1186-11627214215
1036-1318-12907238240

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%2.046.00.04.2%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%4.016.00.020.0%11.029.00.027.5%14.032.02.029.2%
Dividend per Share1.00.03.025.0%1.00.011.08.3%1.00.019.05.0%1.00.039.02.5%1.00.047.02.1%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%4.016.00.020.0%11.029.00.027.5%14.032.02.029.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aldeyra The compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.222-0.159-28%-0.165-26%0.029-872%0.032-788%
Book Value Per Share--1.4291.749-18%2.272-37%2.135-33%1.372+4%
Current Ratio--6.8055.954+14%9.764-30%11.923-43%12.262-45%
Debt To Asset Ratio--0.2750.221+24%0.170+61%0.194+41%0.165+67%
Debt To Equity Ratio--0.3790.286+32%0.205+84%0.252+50%0.208+82%
Dividend Per Share---0.004-100%-0%0.001-100%0.000-100%
Eps---0.254-0.188-26%-0.192-24%-0.208-18%-0.164-35%
Free Cash Flow Per Share---0.134-0.129-4%-0.176+32%-0.176+31%-0.1340%
Free Cash Flow To Equity Per Share---0.137-0.134-3%-0.178+29%163306.078-100%81653.067-100%
Gross Profit Margin--1.0001.093-9%1.0000%1.019-2%1.009-1%
Intrinsic Value_10Y_max---4.182--------
Intrinsic Value_10Y_min---7.049--------
Intrinsic Value_1Y_max---0.519--------
Intrinsic Value_1Y_min---0.727--------
Intrinsic Value_3Y_max---1.483--------
Intrinsic Value_3Y_min---2.180--------
Intrinsic Value_5Y_max---2.356--------
Intrinsic Value_5Y_min---3.616--------
Market Cap287029072.000-12%320972344.000230456952.000+39%475801304.000-33%368984209.000-13%396369581.300-19%
Net Profit Margin----3.0260%-0%-0.6050%0.044-100%
Operating Margin----2.6990%-0%-0.5400%0.074-100%
Operating Ratio---3.883-100%-0%0.777-100%0.043-100%
Pb Ratio3.373-12%3.7722.310+63%3.533+7%3.433+10%10.011-62%
Pe Ratio-4.748+11%-5.310-6.313+19%-10.886+105%-8.029+51%-14.864+180%
Price Per Share4.820-12%5.3903.870+39%7.990-33%6.196-13%6.656-19%
Price To Free Cash Flow Ratio-8.998+11%-10.06221.437-147%-11.659+16%-3.797-62%-15.717+56%
Price To Total Gains Ratio-21.721+11%-24.289-41.042+69%-51.438+112%-30.523+26%-26.869+11%
Quick Ratio--6.8426.738+2%10.041-32%16.069-57%16.879-59%
Return On Assets---0.129-0.088-32%-0.067-48%-0.090-30%-0.132+2%
Return On Equity---0.178-0.115-35%-0.081-54%-0.116-34%-0.162-9%
Total Gains Per Share---0.222-0.155-30%-0.165-26%0.030-850%0.033-779%
Usd Book Value--85095704.000104155128.500-18%135285545.000-37%127142871.150-33%81679019.000+4%
Usd Book Value Change Per Share---0.222-0.159-28%-0.165-26%0.029-872%0.032-788%
Usd Book Value Per Share--1.4291.749-18%2.272-37%2.135-33%1.372+4%
Usd Dividend Per Share---0.004-100%-0%0.001-100%0.000-100%
Usd Eps---0.254-0.188-26%-0.192-24%-0.208-18%-0.164-35%
Usd Free Cash Flow---7974915.000-7667865.500-4%-10510357.000+32%-10470068.650+31%-7965265.5500%
Usd Free Cash Flow Per Share---0.134-0.129-4%-0.176+32%-0.176+31%-0.1340%
Usd Free Cash Flow To Equity Per Share---0.137-0.134-3%-0.178+29%163306.078-100%81653.067-100%
Usd Market Cap287029072.000-12%320972344.000230456952.000+39%475801304.000-33%368984209.000-13%396369581.300-19%
Usd Price Per Share4.820-12%5.3903.870+39%7.990-33%6.196-13%6.656-19%
Usd Profit---15112983.000-11198909.750-26%-11050192.750-27%-12337439.350-18%-9722012.550-36%
Usd Revenue---98155.000-100%-0%19631.000-100%603043588914.350-100%
Usd Total Gains Per Share---0.222-0.155-30%-0.165-26%0.030-850%0.033-779%
 EOD+3 -5MRQTTM+8 -26YOY+7 -225Y+7 -2710Y+8 -28

3.3 Fundamental Score

Let's check the fundamental score of Aldeyra The based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.748
Price to Book Ratio (EOD)Between0-13.373
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than16.842
Current Ratio (MRQ)Greater than16.805
Debt to Asset Ratio (MRQ)Less than10.275
Debt to Equity Ratio (MRQ)Less than10.379
Return on Equity (MRQ)Greater than0.15-0.178
Return on Assets (MRQ)Greater than0.05-0.129
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Aldeyra The based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.914
Ma 20Greater thanMa 504.915
Ma 50Greater thanMa 1005.221
Ma 100Greater thanMa 2005.061
OpenGreater thanClose4.910
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Aldeyra The

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Fundamental data was last updated by Penke on 2024-11-14 09:36:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Aldeyra earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aldeyra to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aldeyra The:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-302.6%+302.6%
TTM-302.6%YOY--302.6%
TTM-302.6%5Y-60.5%-242.1%
5Y-60.5%10Y4.4%-64.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--112.2%+112.2%
TTM-302.6%-221.4%-81.2%
YOY--210.0%+210.0%
5Y-60.5%-342.2%+281.7%
10Y4.4%-464.5%+468.9%
4.3.1.2. Return on Assets

Shows how efficient Aldeyra is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aldeyra to the Biotechnology industry mean.
  • -12.9% Return on Assets means that Aldeyra generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aldeyra The:

  • The MRQ is -12.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.9%TTM-8.8%-4.1%
TTM-8.8%YOY-6.7%-2.1%
TTM-8.8%5Y-9.0%+0.2%
5Y-9.0%10Y-13.2%+4.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.9%-11.3%-1.6%
TTM-8.8%-11.7%+2.9%
YOY-6.7%-11.3%+4.6%
5Y-9.0%-12.7%+3.7%
10Y-13.2%-14.1%+0.9%
4.3.1.3. Return on Equity

Shows how efficient Aldeyra is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aldeyra to the Biotechnology industry mean.
  • -17.8% Return on Equity means Aldeyra generated $-0.18 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aldeyra The:

  • The MRQ is -17.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.8%TTM-11.5%-6.3%
TTM-11.5%YOY-8.1%-3.4%
TTM-11.5%5Y-11.6%+0.1%
5Y-11.6%10Y-16.2%+4.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.8%-14.2%-3.6%
TTM-11.5%-15.9%+4.4%
YOY-8.1%-14.3%+6.2%
5Y-11.6%-18.5%+6.9%
10Y-16.2%-19.3%+3.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aldeyra The.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Aldeyra is operating .

  • Measures how much profit Aldeyra makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aldeyra to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aldeyra The:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-269.9%+269.9%
TTM-269.9%YOY--269.9%
TTM-269.9%5Y-54.0%-215.9%
5Y-54.0%10Y7.4%-61.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--222.9%+222.9%
TTM-269.9%-310.7%+40.8%
YOY--223.5%+223.5%
5Y-54.0%-387.1%+333.1%
10Y7.4%-498.5%+505.9%
4.3.2.2. Operating Ratio

Measures how efficient Aldeyra is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aldeyra The:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM3.883-3.883
TTM3.883YOY-+3.883
TTM3.8835Y0.777+3.106
5Y0.77710Y0.043+0.733
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.465-2.465
TTM3.8833.253+0.630
YOY-3.298-3.298
5Y0.7774.788-4.011
10Y0.0436.494-6.451
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aldeyra The.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aldeyra is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.80 means the company has $6.80 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aldeyra The:

  • The MRQ is 6.805. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.954. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.805TTM5.954+0.850
TTM5.954YOY9.764-3.809
TTM5.9545Y11.923-5.969
5Y11.92310Y12.262-0.338
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.8053.637+3.168
TTM5.9543.890+2.064
YOY9.7644.666+5.098
5Y11.9235.953+5.970
10Y12.2626.277+5.985
4.4.3.2. Quick Ratio

Measures if Aldeyra is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aldeyra to the Biotechnology industry mean.
  • A Quick Ratio of 6.84 means the company can pay off $6.84 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aldeyra The:

  • The MRQ is 6.842. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.738. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.842TTM6.738+0.104
TTM6.738YOY10.041-3.303
TTM6.7385Y16.069-9.331
5Y16.06910Y16.879-0.810
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.8423.086+3.756
TTM6.7383.451+3.287
YOY10.0414.456+5.585
5Y16.0695.931+10.138
10Y16.8796.436+10.443
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aldeyra The.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Aldeyra assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aldeyra to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.27 means that Aldeyra assets are financed with 27.5% credit (debt) and the remaining percentage (100% - 27.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aldeyra The:

  • The MRQ is 0.275. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.221. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.275TTM0.221+0.054
TTM0.221YOY0.170+0.051
TTM0.2215Y0.194+0.027
5Y0.19410Y0.165+0.030
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2750.350-0.075
TTM0.2210.344-0.123
YOY0.1700.310-0.140
5Y0.1940.365-0.171
10Y0.1650.382-0.217
4.5.4.2. Debt to Equity Ratio

Measures if Aldeyra is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aldeyra to the Biotechnology industry mean.
  • A Debt to Equity ratio of 37.9% means that company has $0.38 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aldeyra The:

  • The MRQ is 0.379. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.286. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.379TTM0.286+0.092
TTM0.286YOY0.205+0.081
TTM0.2865Y0.252+0.034
5Y0.25210Y0.208+0.044
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3790.394-0.015
TTM0.2860.432-0.146
YOY0.2050.380-0.175
5Y0.2520.451-0.199
10Y0.2080.490-0.282
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aldeyra generates.

  • Above 15 is considered overpriced but always compare Aldeyra to the Biotechnology industry mean.
  • A PE ratio of -5.31 means the investor is paying $-5.31 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aldeyra The:

  • The EOD is -4.748. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.310. Based on the earnings, the company is expensive. -2
  • The TTM is -6.313. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.748MRQ-5.310+0.561
MRQ-5.310TTM-6.313+1.003
TTM-6.313YOY-10.886+4.573
TTM-6.3135Y-8.029+1.716
5Y-8.02910Y-14.864+6.835
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.748-2.303-2.445
MRQ-5.310-2.403-2.907
TTM-6.313-3.148-3.165
YOY-10.886-3.251-7.635
5Y-8.029-6.084-1.945
10Y-14.864-6.764-8.100
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aldeyra The:

  • The EOD is -8.998. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -10.062. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 21.437. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD-8.998MRQ-10.062+1.064
MRQ-10.062TTM21.437-31.499
TTM21.437YOY-11.659+33.096
TTM21.4375Y-3.797+25.234
5Y-3.79710Y-15.717+11.920
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.998-3.042-5.956
MRQ-10.062-3.234-6.828
TTM21.437-3.719+25.156
YOY-11.659-4.557-7.102
5Y-3.797-8.332+4.535
10Y-15.717-9.276-6.441
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Aldeyra is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.77 means the investor is paying $3.77 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aldeyra The:

  • The EOD is 3.373. Based on the equity, the company is fair priced.
  • The MRQ is 3.772. Based on the equity, the company is fair priced.
  • The TTM is 2.310. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.373MRQ3.772-0.399
MRQ3.772TTM2.310+1.462
TTM2.310YOY3.533-1.224
TTM2.3105Y3.433-1.123
5Y3.43310Y10.011-6.578
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.3731.943+1.430
MRQ3.7722.051+1.721
TTM2.3102.356-0.046
YOY3.5332.454+1.079
5Y3.4333.714-0.281
10Y10.0114.378+5.633
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aldeyra The.

4.8.1. Institutions holding Aldeyra The

Institutions are holding 60.545% of the shares of Aldeyra The.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30Perceptive Advisors LLC15.61020.739592758516822657.9392
2024-06-30Knoll Capital Management LP9.214712.2123547551600
2024-06-30Vanguard Group Inc6.2980.00023742386-126693-3.2745
2024-06-30BlackRock Inc6.09530.000336219493111629.3984
2024-06-30Kennedy Capital Management Inc2.69210.1132159967328151821.357
2024-06-30Geode Capital Management, LLC1.91520.0003113804310984510.6833
2024-06-30State Street Corp1.61170.0001957720181511.9318
2024-06-30Eagle Asset Management, Inc.1.41630.0147841571-126244-13.0442
2024-06-30Dimensional Fund Advisors, Inc.1.1310.0006672057-210153-23.8212
2024-06-30Morgan Stanley - Brokerage Accounts1.04810.0001622808-76284-10.9119
2024-06-30Federated Hermes Inc0.8940.00425312215312210
2024-06-30Renaissance Technologies Corp0.8470.0028503300-224390-30.8359
2024-06-30Wells Fargo & Co0.66520.000339529779932.0638
2024-09-30PFG Investments, LLC0.65030.1345386447-9800-2.4732
2024-06-30Northern Trust Corp0.64880.0002385507-3680-0.9456
2024-06-30Bank of America Corp0.6370.0001378490-20461-5.1287
2024-06-30Los Angeles Capital Management LLC0.56320.004334669-46104-12.108
2024-06-30D. E. Shaw & Co LP0.54180.001321938-225702-41.2136
2024-06-30Deutsche Bank AG0.50550.000530035279652.7241
2024-06-30Johnson & Johnson0.50430.247629966900
Total 53.489713.476531784464+880609+2.8%

4.9.2. Funds holding Aldeyra The

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Vanguard Total Stock Mkt Idx Inv2.95970.0005175871400
2024-10-31iShares Russell 2000 ETF2.18160.01011296318-2912-0.2241
2024-09-30Kennedy Micro Cap1.44650.946859506-273368-24.1305
2024-09-30Vanguard Institutional Extnd Mkt Idx Tr1.17390.0035697567-37474-5.0982
2024-09-30Vanguard Explorer Inv1.14440.016368000400
2024-10-31Invesco Dorsey Wright SmallCap Momt ETF1.06720.343663412000
2024-08-31Fidelity Small Cap Index0.85850.0108510128-9967-1.9164
2024-10-31iShares Russell 2000 Value ETF0.69890.017741531100
2024-09-30Eagle Small Cap Growth – Institutional0.63280.2229376024-83480-18.1674
2024-10-31State St Russell Sm/Mid Cp® Indx NL Cl C0.54710.0038325100-10200-3.0421
2024-09-30Federated Hermes MDT Small Cap Growth IS0.53880.3417320145175665.8054
2024-09-30Federated Hermes MDT SCG Institutional0.53880.3417320145175665.8054
2024-09-30Kennedy Extended Small Cap0.49260.1412927215536823.3273
2024-09-30DWS ESG Biotech LC0.44940.374326707010.0004
2024-09-30Fidelity Extended Market Index0.42540.0033252763-24481-8.8301
2024-09-30Carillon Eagle Small Cap Growth A0.39490.2554234668-30483-11.4965
2024-09-30Vanguard Russell 2000 ETF0.3850.00992287672793013.9068
2024-09-30Federated Hermes MDT Small Cap Core IS0.38340.088222781400
2024-09-30Federated Hermes MDT SCC Institutional0.38340.088222781400
2024-09-30Kennedy Small Cap Select0.3690.51492192562192560
Total 17.07133.733810143955-134678-1.3%

5.3. Insider Transactions

Insiders are holding 2.441% of the shares of Aldeyra The.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-05Perceptive Advisors LlcBUY377124.74
2024-04-03Perceptive Advisors LlcBUY3098474.09
2024-04-01Perceptive Advisors LlcBUY83743.25
2024-03-11Bruce GreenbergSELL132013.41
2024-03-11Todd C BradySELL979143.27
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Interest Expense  539-24514-16499-21478-957-479



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets117,319
Total Liabilities32,224
Total Stockholder Equity85,096
 As reported
Total Liabilities 32,224
Total Stockholder Equity+ 85,096
Total Assets = 117,319

Assets

Total Assets117,319
Total Current Assets116,721
Long-term Assets599
Total Current Assets
Cash And Cash Equivalents 28,120
Short-term Investments 44,624
Other Current Assets 43,977
Total Current Assets  (as reported)116,721
Total Current Assets  (calculated)116,721
+/-0
Long-term Assets
Property Plant Equipment 331
Long-term Assets Other 267
Long-term Assets  (as reported)599
Long-term Assets  (calculated)599
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities17,153
Long-term Liabilities15,070
Total Stockholder Equity85,096
Total Current Liabilities
Short-term Debt 543
Accounts payable 187
Other Current Liabilities 10,423
Total Current Liabilities  (as reported)17,153
Total Current Liabilities  (calculated)11,153
+/- 6,000
Long-term Liabilities
Long-term Liabilities  (as reported)15,070
Long-term Liabilities  (calculated)0
+/- 15,070
Total Stockholder Equity
Common Stock60
Retained Earnings -434,302
Accumulated Other Comprehensive Income 67
Other Stockholders Equity 519,271
Total Stockholder Equity (as reported)85,096
Total Stockholder Equity (calculated)85,096
+/-0
Other
Cash and Short Term Investments 72,744
Common Stock Shares Outstanding 59,530
Current Deferred Revenue6,000
Liabilities and Stockholders Equity 117,319
Net Debt -12,507
Net Working Capital 99,567
Short Long Term Debt Total 15,613



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
1,977
0
0
2,819
3,743
2,891
11,805
10,351
8,787
15,931
33,878
31,350
28,205
23,437
32,884
29,191
25,188
31,532
26,468
49,229
44,175
40,776
43,286
37,132
95,091
88,128
73,839
77,441
75,518
63,029
71,627
88,324
83,353
147,306
256,427
247,218
233,137
222,693
201,015
189,692
181,292
168,219
155,616
147,282
148,327
141,302
126,044
117,319
117,319126,044141,302148,327147,282155,616168,219181,292189,692201,015222,693233,137247,218256,427147,30683,35388,32471,62763,02975,51877,44173,83988,12895,09137,13243,28640,77644,17549,22926,46831,53225,18829,19132,88423,43728,20531,35033,87815,9318,78710,35111,8052,8913,7432,819001,977
   > Total Current Assets 
1,977
0
0
2,769
3,271
2,155
11,805
10,345
8,760
15,898
33,837
31,226
28,088
23,309
32,809
29,126
25,131
31,473
26,342
49,053
43,966
40,605
43,071
36,845
94,769
86,996
72,856
77,020
75,169
62,752
71,423
88,193
83,059
147,073
256,261
246,772
232,753
222,355
200,741
189,483
181,023
168,017
155,479
147,210
143,347
133,527
121,790
116,721
116,721121,790133,527143,347147,210155,479168,017181,023189,483200,741222,355232,753246,772256,261147,07383,05988,19371,42362,75275,16977,02072,85686,99694,76936,84543,07140,60543,96649,05326,34231,47325,13129,12632,80923,30928,08831,22633,83715,8988,76010,34511,8052,1553,2712,769001,977
       Cash And Cash Equivalents 
1,224
0
0
2,764
3,262
2,146
11,536
10,142
8,527
15,721
33,570
30,618
14,649
10,149
17,608
14,569
12,015
19,303
14,610
33,104
20,023
20,964
24,606
18,009
47,357
44,298
39,400
51,604
44,426
38,543
60,689
86,176
77,858
138,442
249,739
241,369
229,791
158,909
121,012
128,651
144,419
165,028
151,676
143,335
142,823
52,492
31,030
28,120
28,12031,03052,492142,823143,335151,676165,028144,419128,651121,012158,909229,791241,369249,739138,44277,85886,17660,68938,54344,42651,60439,40044,29847,35718,00924,60620,96420,02333,10414,61019,30312,01514,56917,60810,14914,64930,61833,57015,7218,52710,14211,5362,1463,2622,764001,224
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
12,942
12,877
14,941
14,307
12,898
11,910
11,211
14,807
22,923
17,975
17,073
17,134
46,242
37,827
30,057
24,567
28,939
22,834
5,501
0
0
0
0
0
0
57,957
75,677
56,679
29,882
0
0
0
0
30,545
49,302
44,624
44,62449,30230,545000029,88256,67975,67757,9570000005,50122,83428,93924,56730,05737,82746,24217,13417,07317,97522,92314,80711,21111,91012,89814,30714,94112,87712,942000000000000
       Net Receivables 
750
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,000
0
17,000
11,000
44,000
39,000
32,000
26,000
28,000
23,000
10,000
15,000
25,000
50,000
125,000
125,000
125,000
65,000
79,000
21,500
3,242
24
0
0
0
50,000
40,000
0
040,00050,000000243,24221,50079,00065,000125,000125,000125,00050,00025,00015,00010,00023,00028,00026,00032,00039,00044,00011,00017,000018,0000000000000000000000750
       Other Current Assets 
3
0
0
4
8
10
270
203
233
177
267
607
498
284
260
250
219
261
521
1,142
1,019
1,667
1,393
1,703
1,170
4,872
3,399
849
1,804
1,375
5,233
2,017
407
216
1,297
870
558
433
328
4,154
6,722
2,989
259
212
524
490
46,354
43,977
43,97746,3544905242122592,9896,7224,1543284335588701,2972164072,0175,2331,3751,8048493,3994,8721,1701,7031,3931,6671,0191,1425212612192502602844986072671772332032701084003
   > Long-term Assets 
0
0
0
50
472
735
0
6
27
33
41
125
117
127
75
66
56
58
126
177
209
171
215
286
322
1,132
983
421
349
277
205
132
293
233
166
446
384
338
274
209
269
202
137
72
4,980
7,774
4,254
599
5994,2547,7744,980721372022692092743383844461662332931322052773494219831,132322286215171209177126585666751271171254133276073547250000
       Property Plant Equipment 
0
0
0
0
0
0
0
6
13
13
41
88
80
81
75
66
56
58
48
38
43
171
215
243
235
594
491
421
349
277
205
132
293
233
166
446
384
338
274
209
269
202
137
72
517
456
394
331
331394456517721372022692092743383844461662332931322052773494214915942352432151714338485856667581808841131360000000
       Other Assets 
0
0
0
0
472
736
0
0
14
20
0
36
36
46
0
0
0
0
78
138
166
0
0
43
87
538
492
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000049253887430016613878000046363602014007364720000
> Total Liabilities 
27,132
0
0
14,583
2,128
4,027
1,990
2,087
2,503
2,105
2,353
2,655
3,326
2,910
3,366
3,520
3,538
3,537
3,128
3,324
4,574
4,775
6,305
8,537
8,473
9,648
6,506
26,562
27,436
19,557
18,838
19,154
23,844
21,232
22,747
27,548
27,402
32,004
26,986
27,498
30,284
30,976
25,733
24,275
28,532
27,882
27,733
32,224
32,22427,73327,88228,53224,27525,73330,97630,28427,49826,98632,00427,40227,54822,74721,23223,84419,15418,83819,55727,43626,5626,5069,6488,4738,5376,3054,7754,5743,3243,1283,5373,5383,5203,3662,9103,3262,6552,3532,1052,5032,0871,9904,0272,12814,5830027,132
   > Total Current Liabilities 
363
0
0
201
605
692
1,175
846
1,328
1,036
1,391
1,374
2,115
1,808
2,373
2,637
2,299
2,409
2,112
2,419
3,354
3,667
5,310
7,654
8,473
9,492
6,390
12,116
12,908
4,887
4,920
6,461
12,409
11,091
7,409
11,942
11,773
16,354
16,243
24,195
15,361
16,008
15,605
21,617
22,260
21,676
27,595
17,153
17,15327,59521,67622,26021,61715,60516,00815,36124,19516,24316,35411,77311,9427,40911,09112,4096,4614,9204,88712,90812,1166,3909,4928,4737,6545,3103,6673,3542,4192,1122,4092,2992,6372,3731,8082,1151,3741,3911,0361,3288461,17569260520100363
       Short-term Debt 
167
0
0
0
143
388
407
0
78
194
310
0
78
194
310
427
78
194
310
427
116
233
349
465
0
221
212
219
226
172
1,010
2,318
3,893
5,271
118
222
230
236
5,168
12,634
1,161
1,145
6,024
13,527
15,625
15,452
15,752
543
54315,75215,45215,62513,5276,0241,1451,16112,6345,1682362302221185,2713,8932,3181,010172226219212221046534923311642731019478427310194780310194780407388143000167
       Short Long Term Debt 
0
0
0
0
0
0
0
0
78
0
0
0
78
0
0
0
78
194
1,327
427
116
233
349
465
0
221
0
0
0
0
894
2,259
3,660
5,095
0
0
0
0
4,926
12,449
912
954
5,894
13,461
15,147
15,205
15,242
0
015,24215,20515,14713,4615,89495491212,4494,92600005,0953,6602,259894000022104653492331164271,32719478000780007800000000
       Accounts payable 
73
0
0
65
342
166
556
482
341
406
629
744
851
578
823
734
275
695
763
485
1,001
1,619
802
3,442
3,052
4,013
2,774
572
808
1,073
217
124
382
449
1,094
468
1,020
2,443
264
1,307
134
430
271
247
1,338
280
254
187
1872542801,3382472714301341,3072642,4431,0204681,0944493821242171,0738085722,7744,0133,0523,4428021,6191,001485763695275734823578851744629406341482556166342650073
       Other Current Liabilities 
124
0
0
136
120
138
211
364
909
436
452
630
1,186
1,036
1,240
1,477
1,946
1,520
1,039
1,507
2,236
1,815
4,159
3,746
5,421
5,257
3,404
11,325
11,873
3,642
3,694
4,019
8,135
5,372
6,196
11,252
10,523
13,676
10,810
10,254
14,066
14,434
9,310
7,843
5,297
5,944
5,588
10,423
10,4235,5885,9445,2977,8439,31014,43414,06610,25410,81013,67610,52311,2526,1965,3728,1354,0193,6943,64211,87311,3253,4045,2575,4213,7464,1591,8152,2361,5071,0391,5201,9461,4771,2401,0361,18663045243690936421113812013600124
   > Long-term Liabilities 
26,768
0
0
14,382
1,523
3,336
816
1,241
1,175
1,069
962
1,281
1,211
1,102
993
883
1,239
1,128
1,016
905
1,220
1,108
995
883
0
157
116
14,445
14,528
14,670
13,917
12,693
11,434
10,141
15,338
15,606
15,629
15,650
10,744
3,303
14,923
14,968
10,128
2,657
6,272
6,206
139
15,070
15,0701396,2066,2722,65710,12814,96814,9233,30310,74415,65015,62915,60615,33810,14111,43412,69313,91714,67014,52814,44511615708839951,1081,2209051,0161,1281,2398839931,1021,2111,2819621,0691,1751,2418163,3361,52314,3820026,768
       Long term Debt Total 
0
0
0
0
0
972
816
1,241
1,175
1,069
962
1,281
1,211
1,102
993
883
1,239
1,128
1,016
905
1,220
1,108
995
883
0
0
0
14,387
14,528
14,670
13,917
12,693
11,434
10,141
15,338
15,421
15,504
15,587
10,744
3,303
14,923
14,968
0
0
0
0
0
0
00000014,96814,9233,30310,74415,58715,50415,42115,33810,14111,43412,69313,91714,67014,52814,3870008839951,1081,2209051,0161,1281,2398839931,1021,2111,2819621,0691,1751,24181697200000
       Long term Debt 
2,535
0
0
0
4,648
972
816
1,241
1,175
1,069
962
1,281
1,211
1,102
993
883
1,239
1,128
1,016
905
1,220
1,108
995
883
0
157
0
14,387
14,528
14,670
13,917
12,693
11,434
10,141
15,338
15,421
15,504
15,587
10,744
3,303
14,923
14,968
10,128
2,657
0
0
0
0
00002,65710,12814,96814,9233,30310,74415,58715,50415,42115,33810,14111,43412,69313,91714,67014,52814,387015708839951,1081,2209051,0161,1281,2398839931,1021,2111,2819621,0691,1751,2418169724,6480002,535
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
378
328
278
226
172
116
59
233
176
118
407
355
299
243
185
249
190
130
66
511
453
394
0
039445351166130190249185243299355407118176233591161722262783283780000000000000000000000000
       Warrants
0
0
0
0
0
77,018
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000077,01800000
       Other Liabilities 
24,234
0
0
0
394
604
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000060439400024,234
       Long-term Liabilities Other 
0
0
0
0
0
2,231
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
157
116
59
0
0
0
0
0
0
0
185
125
63
0
0
0
0
0
0
0
0
0
0
00000000006312518500000005911615700000000000000000002,23100000
       Deferred Long Term Liability 
0
0
0
0
0
132
0
0
14
0
0
0
36
0
0
0
0
0
0
0
166
0
0
43
87
538
492
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000492538874300166000000036000140013200000
> Total Stockholder Equity
-25,155
0
0
-11,764
1,615
-1,137
9,815
8,264
6,284
13,827
31,525
28,695
24,878
20,527
29,518
25,672
21,650
27,995
23,340
45,905
39,601
36,001
36,981
28,595
86,618
78,480
67,333
50,879
48,082
43,473
52,790
69,170
59,509
126,074
233,680
219,670
205,736
190,689
174,029
162,194
151,008
137,243
129,883
123,008
119,795
113,419
98,310
85,096
85,09698,310113,419119,795123,008129,883137,243151,008162,194174,029190,689205,736219,670233,680126,07459,50969,17052,79043,47348,08250,87967,33378,48086,61828,59536,98136,00139,60145,90523,34027,99521,65025,67229,51820,52724,87828,69531,52513,8276,2848,2649,815-1,1371,615-11,76400-25,155
   Common Stock
4
0
0
4
4
0
6
6
6
7
10
10
10
10
12
13
13
15
15
19
19
20
21
21
26
27
27
27
29
30
33
39
39
48
58
58
58
58
58
59
59
59
59
59
59
59
59
60
60595959595959595958585858584839393330292727272621212019191515131312101010107666044004
   Retained Earnings Total Equity
0
0
0
0
0
40,923
-42,058
-44,067
-46,512
-48,648
-50,880
-54,246
-58,602
-63,569
-67,872
-72,650
-77,301
-82,392
-87,701
-92,687
-99,642
-108,039
-117,089
-127,902
-138,535
-154,159
-167,486
-186,201
-199,362
-209,230
-216,750
-225,624
-236,916
-248,206
-263,143
-278,937
-294,692
-311,480
-329,261
-343,814
-356,717
-372,332
0
0
0
0
0
0
000000-372,332-356,717-343,814-329,261-311,480-294,692-278,937-263,143-248,206-236,916-225,624-216,750-209,230-199,362-186,201-167,486-154,159-138,535-127,902-117,089-108,039-99,642-92,687-87,701-82,392-77,301-72,650-67,872-63,569-58,602-54,246-50,880-48,648-46,512-44,067-42,05840,92300000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
-11,805
-10,351
0
0
0
0
-8
2
5
7
0
-5
-5
-1
-18
-16
-3
-5
-9
7
13
6
6
58
5
0
0
0
0
0
0
-62
-286
-286
-104
0
0
0
0
-3
-10
67
67-10-30000-104-286-286-6200000055866137-9-5-3-16-18-1-5-50752-80000-10,351-11,805000000
   Capital Surplus 
0
0
0
0
0
1,277
51,867
52,325
52,790
62,468
82,395
82,932
83,479
84,085
97,372
98,302
98,938
110,377
111,031
138,574
139,242
144,037
154,052
156,481
225,136
232,605
234,779
237,048
247,410
252,616
269,502
294,755
296,386
374,232
496,764
498,549
500,369
502,172
503,518
506,235
507,770
509,517
0
0
0
0
0
0
000000509,517507,770506,235503,518502,172500,369498,549496,764374,232296,386294,755269,502252,616247,410237,048234,779232,605225,136156,481154,052144,037139,242138,574111,031110,37798,93898,30297,37284,08583,47982,93282,39562,46852,79052,32551,8671,27700000
   Treasury Stock000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
897
42,935
1,277
51,867
52,325
52,790
62,468
82,395
82,932
83,479
84,085
97,372
98,302
98,938
110,377
111,031
138,574
139,242
144,037
154,052
156,481
225,136
232,605
234,779
237,048
247,410
252,616
269,502
294,755
296,386
374,232
496,764
498,549
500,369
502,172
503,518
506,235
507,770
509,517
511,144
512,455
513,995
515,704
517,449
519,271
519,271517,449515,704513,995512,455511,144509,517507,770506,235503,518502,172500,369498,549496,764374,232296,386294,755269,502252,616247,410237,048234,779232,605225,136156,481154,052144,037139,242138,574111,031110,37798,93898,30297,37284,08583,47982,93282,39562,46852,79052,32551,8671,27742,935897000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.